Antibodies that bind to cis and uses thereof
Embodiments that are provided for herein relate to antibodies and compositions that bind to C1s. Also provided are methods of producing the antibodies of the present disclosure, as well as uses of the provided antibodies and compositions for the treatment of C1s mediated diseases and disorders.
1. An antibody, or an antigen binding fragment thereof, wherein the antibody, or the antigen binding fragment thereof, comprises:
a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1 has the amino acid sequence of SEQ ID NO: 61, the HCDR2 has the amino acid sequence of SEQ ID NO: 62, and the HCDR3 has the amino acid sequence of SEQ ID NO: 78; and
a light chain variable region comprising light chain LCDR1, LCDR3, and LCDR3 sequences, wherein the LCDR1 has the amino acid sequence of SEQ ID NO: 64, the LCDR2 has the amino acid sequence of SEQ ID NO: 65, and the LCDR3 has the amino acid sequence of SEQ ID NO: 79.
2. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the heavy chain variable region comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 342.
3. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 342.
4. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the heavy chain variable region comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 17.
5. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 17.
6. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the heavy chain variable region comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 454.
7. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 454.
8. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the antibody, or the antigen binding fragment thereof, comprises a heavy chain that is at least 95% identical to the amino acid sequence of SEQ ID NO: 381.
9. The antibody, or the antigen binding fragment thereof, of claim 1 , o wherein the antibody, or the antigen binding fragment thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 381.
10. The antibody, or the antigen binding fragment thereof, of claim 1 , herein the antibody, or the antigen binding fragment thereof, comprises a heavy chain that is at least 95% identical to the amino acid sequence of SEQ ID NO: 185.
11. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the antibody, or the antigen binding fragment thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 185.
12. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the light chain variable region comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 18.
13. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 18.
14. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the antibody, or the antigen binding fragment thereof, comprises a light chain that is at least 95% identical to the amino acid sequence of SEQ ID NO: 236.
15. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the antibody, or the antigen binding fragment thereof, comprises a light chain comprising the amino acid sequence of SEQ ID NO: 236.
16. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the antibody, or the antigen binding fragment thereof, comprises the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 342, and the light chain variable region comprising the amino acid sequence of SEQ ID NO 18.
17. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the antibody, or the antigen binding fragment thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 381, and a light chain comprising the amino acid sequence of SEQ ID NO: 236.
18. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the antibody, or the antigen binding fragment thereof, comprises the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17, and the light chain variable region comprising the amino acid sequence of SEQ ID NO 18.
19. The antibody, or the antigen binding fragment thereof, of claim 1 , wherein the antibody, or the antigen binding fragment thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 185, and a light chain comprising the amino acid sequence of SEQ ID NO: 236.
20. A pharmaceutical composition comprising the antibody, or the antigen binding fragment thereof, of claim 1 , and a pharmaceutically acceptable excipient.
21. A method of treating a subject with Myasthenia Gravis, hemolysis, Cold Agglutinin Disease, Immune Thrombocytopenia (ITP), Glomerulopathies, Atypical Hemolytic uremic syndrome, antiphospholipid antibody syndrome, transplant rejection, Chronic inflammatory demyelinating polyneuropathy (CIDP), Multifocal motor neuropathy (MMN), Dermatomyositis, or Anti MAG neuropathy, the method comprising administering to the subject the antibody, or the antigen binding fragment thereof, of claim 1 , or a pharmaceutical composition comprising the antibody, or the antigen binding fragment thereof, of claim 1 .
22. The method of claim 21 , wherein the subject is a subject with Myasthenia Gravis.
23. The method of claim 21 , wherein the subject is a subject with Cold Agglutinin Disease.
24. The method of claim 21 , wherein the subject is a subject with Chronic inflammatory demyelinating polyneuropathy (CIDP).
25. The method of claim 21 , wherein the subject is a subject with Multifocal motor neuropathy (MMN).